Skip to main content
Figure 1 | Skeletal Muscle

Figure 1

From: Wnt/β-catenin controls follistatin signalling to regulate satellite cell myogenic potential

Figure 1

Follistatin expression is regulated by canonical Wnt/β-catenin signalling. (A) Schematic depicting the in vitro treatment of myoblasts with rWnt3a. (B) Global heat map ratio representing the difference in gene expression patterns following treatment with recombinant Wnt3a or control BSA protein. Red represents genes that increase in expression relative to the BSA-treated control, while blue represents a decrease. (C) qPCR validation of a subset of genes upregulated following Wnt3a treatment relative to BSA control. Data are presented as the mean ± SEM (n = 3, *P < 0.05, **P < 0.01), normalized to GAPDH and shown relative to BSA control. (D) qPCR validation of a subset of genes downregulated following Wnt3a treatment relative to BSA control. Data are presented as the mean ± SEM (n = 3, *P < 0.05, **P < 0.01), normalized to GAPDH, and shown relative to BSA control. (E) qPCR analysis of Pax7, follistatin, Axin2, and Myh2 expression levels in a myoblast differentiation time-course. Pax7 expression is reduced, while Myh2 expression increases during differentiation. Follistatin expression is upregulated during the first 24 h of differentiation in a similar fashion as the Wnt target Axin2. Data are presented as the mean ± SEM (n = 3), normalized to GAPDH. (F) qPCR analysis of Axin2 and follistatin expression in myoblasts cultured in differentiation media for 24 h, following recombinant Wnt3a, Dkk1, or control BSA protein treatments. Data are presented as the mean ± SEM (n = 3), normalized to GAPDH.

Back to article page